Vmn1r77, a member of the vomeronasal 1 receptor family, plays a crucial role in chemosensory signaling, primarily influenced by variations in intracellular secondary messenger concentrations, particularly cAMP. Chemical compounds like Forskolin, which activates adenylate cyclase, and cyclic AMP itself, a key secondary messenger, directly impact the functional activity of Vmn1r77. Forskolin enhances the signaling cascade of Vmn1r77 by increasing cAMP levels, thereby facilitating a more robust response of this receptor to its specific ligands. Similarly, the exogenous application of cyclic AMP can mimic this effect, providing a direct boost to the receptor's signaling pathway. In addition to these, specific phosphodiesterase inhibitors such as IBMX, Zaprinast, Rolipram, and Milrinone, each targeting different PDE isoforms, prevent the degradation of cAMP. By maintaining elevated levels of cAMP, these compounds indirectly amplify the signaling pathways of GPCRs like Vmn1r77, enhancing its functional activity. This mechanism of action is shared by other PDE inhibitors like Vinpocetine, Cilostazol, Sildenafil, Anagrelide, Pentoxifylline, and Theophylline, each contributing to the sustained activation of Vmn1r77 by increasing intracellular cAMP concentrations.
The functional activity of Vmn1r77 is intricately connected to the cellular levels of cAMP, and the array of compounds that modulate these levels provides a diverse toolkit for influencing Vmn1r77's activation. The selective inhibition of PDEs by Milrinone, Cilostazol, and Anagrelide specifically raises cAMP levels, which in turn enhances the GPCR signaling cascade associated with Vmn1r77. This effect is further echoed by Sildenafil's action on PDE5, leading to a similar outcome. On the other hand, non-selective PDE inhibitors like Pentoxifylline and Theophylline offer a broader approach, elevating cAMP levels and thereby potentiating the signaling pathways of Vmn1r77. Through these diverse yet interconnected mechanisms, each of these compounds plays a pivotal role in modulating the activity of Vmn1r77. This modulation is crucial for the precise functioning of Vmn1r77 in chemosensory signaling, demonstrating the intricate interplay between secondary messengers and GPCR activation in cellular communication processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
Cyclic AMP, as a secondary messenger, directly interacts with GPCR pathways. Elevated cAMP levels can potentiate the signaling cascade associated with Vmn1r77, thereby enhancing its functional activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX acts as a non-selective inhibitor of phosphodiesterases, preventing cAMP degradation. Increased cAMP levels enhance GPCR signaling, including the pathway of Vmn1r77, resulting in increased receptor activity. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterase type 5 (PDE5), increasing cAMP and cGMP levels. Elevated secondary messengers can enhance GPCR signaling, including Vmn1r77's pathway, thereby augmenting its functional activation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram, a selective inhibitor of phosphodiesterase 4 (PDE4), increases intracellular cAMP. This elevation potentiates the signaling pathways of GPCRs like Vmn1r77, enhancing its functional activity. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone, a selective phosphodiesterase 3 (PDE3) inhibitor, increases cAMP levels. This elevation indirectly enhances the signaling of GPCR family members like Vmn1r77, increasing its functional activity. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine inhibits PDE1, increasing cAMP and cGMP levels in cells. The rise in these messengers enhances the signaling pathways associated with GPCRs, including Vmn1r77, augmenting its activation and response. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Cilostazol, a selective inhibitor of phosphodiesterase 3, elevates cAMP levels, enhancing the signaling of GPCRs such as Vmn1r77 and indirectly leading to its increased functional activity. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide, a PDE3 inhibitor, leads to increased cAMP levels, enhancing GPCR signaling pathways. This effect can indirectly increase the functional activity of Vmn1r77. | ||||||
Pentoxifylline | 6493-05-6 | sc-203184 | 1 g | $20.00 | 3 | |
Pentoxifylline, a non-selective phosphodiesterase inhibitor, raises intracellular cAMP levels, potentiating the signaling pathways of GPCRs, including Vmn1r77, thereby enhancing its functional activity. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Theophylline, a non-selective phosphodiesterase inhibitor, increases cAMP levels in cells. Elevated cAMP enhances GPCR-mediated signaling pathways, including those of Vmn1r77, leading to its increased functional activation. | ||||||